The EU did a Brexit trade deal with the pharma industry: it tried to lock in a perceived short-term price advantage at the expense of everything else. Instead of prioritising the speed and security of supplies at any price, the EU prioritised the price. The EU paid 24% less for the Pfizer vaccine than the US, for example. For the Oxford/AstraZeneca vaccine, the price gap is 45%. The UK almost certainly paid a lot more. It is no wonder that the manufacturers are prioritising orders on a first-come, first-serve basis, and from countries that pay the full price. The price difference is macroeconomically irrelevant. But if vaccine shortages lead to longer lockdowns, the indirect effect of that short-sighted policy will be massive.
Related Articles

Climate Crisis
Inside Climate News: US Firms Secure 19 Deals to Export Liquified Natural Gas, Driven in Part by the War in Ukraine
A new report details a flurry of business activity and the potential impact on the climate. President Biden supports increased LNG exports, eager to support European allies desperate to replace Russian gas. Read Here Two […]

Austerity
Bill Mitchell: Greece – the next bailout is just around the corner
January 23, 2018
Mathew D. Rose
Austerity, EU politics, EU-Institutions, National Politics, Neo-Liberalism in the EU, Privatisation
0
Greece has disappeared from the headlines, but its disastrous economic state has changed little. Bill Mitchell looks at the nation that purportedly turned the corner. Read here

Climate Crisis
Common Dreams: Dozens Arrested as Scientists Worldwide Mobilize to Demand ‘Climate Revolution’
“If everyone could see what I see coming,” said one scientist, “society would switch into climate emergency mode and end fossil fuels in just a few years.” Read Here Scientists engage in civil disobedience on […]
Be the first to comment